Tandem Diabetes Care

TNDM

Market cap $1.72B

Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S.

Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge. TNDM's shift to a pay-as-you-go model will temporarily compress reported revenue but should enable smoother, recurring income and improved long-term economics.

Tandem saw robust demand for its insulin pumps in the fourth quarter. Management expects further shipment growth in 2026.

The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported better-than-expected fourth-quarter financial results on Thursday.

Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.

Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.